CA-MICROVENTION,-INC.
16.11.2023 15:01:37 CET | Business Wire | Press release
MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, is celebrating a decade of legacy innovation commemorating the anniversary of SOFIA™ and SOFIA™ Flow Plus Aspiration Catheters, with more than half a million worldwide procedures performed across 170 countries, and 30+ articles published globally since it was first introduced ten years ago. The announcement was made today at the 2023 SVIN Annual Meeting in Miami, Florida, where MicroVention is exhibiting in booth number 304.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231116517067/en/
MicroVention Celebrates 10-Year Anniversary and Legacy of SOFIA™ Aspiration Catheters; More than 500,000 Procedures Performed Worldwide Across 170 Countries (Graphic: Business Wire)
From access to revascularization, today MicroVention now offers a fully integrated and streamlined portfolio of stroke solutions including SOFIA™, SOFIA™ Flow Plus, as well as ERIC™ Retrieval Device, BOBBY™ Balloon Guide Catheter, WEDGE™ Microcatheter, HEADWAY™ Microcatheters and TRAXCESS™ Guidewires.
MicroVention’s SOFIA Aspiration Catheter is designed for tracking to the occlusion site and the aspiration of thrombus. SOFIA’s exceptionally soft distal segment allows for excellent navigability and trackability through tortuous anatomy, enabling SOFIA to reliably reach the occlusion site. The device’s hybrid braid coil design provides enhanced control while its coil reinforcement provides lumen integrity, flexibility and excellent shape retention.
“Ten years ago, MicroVention set the standard and re-envisioned catheter innovation through the development of SOFIA Catheters. In this developmental milestone, we committed to meaningful advancements in stroke innovations to help improve patient lives around the world, and we will continue on this path with current and future investments,” said Carsten Schroeder, President and CEO, MicroVention, Inc. “We are thankful for our remarkable partnerships with many physicians around the world where we work side by side to identify the evolving needs in patient care, and then transform those insights into cutting-edge technologies. Every new technology developed is inspired by the breakthrough that came before, now evidenced with MicroVention’s fully integrated comprehensive portfolio of stroke solutions.”
Leveraging the company’s in-house R&D and manufacturing expertise and precision, MicroVention’s fully-integrated and streamlined portfolio of stroke solutions delivers compatibility, versatility, and speed. MicroVention’s integrated stroke solution portfolio includes:
- SOFIA™ Flow Plus Aspiration Catheters: Take control with renowned trackability and proven clinical performance
- ERIC™ Retrieval Device: Reshaping ischemic stroke treatment by delivering thrombus control, procedural efficiency and versatility when every second counts
- BOBBY™ Balloon Guide Catheter: BOBBY adds reliable flow arrest to procedures with optimized compatibility, streamlined prep, and next-generation balloon technology
- WEDGE™ Microcatheter: Create a smooth path in extreme tortuosity for aspiration catheters with a navigation aid that minimizes the ledge effect
- HEADWAY™ Microcatheters: Engineered for excellent trackability, featuring a low-profile outer diameter, providing versatility, reliability, and fast access
- TRAXCESS™ Guidewires: Track through challenging anatomies with tip softness and flexibility
About MicroVention, Inc.
Founded in 1997, MicroVention develops and markets medical devices that enable or significantly improve treatment of cerebrovascular diseases. In 2006, Terumo Corporation, a major worldwide medical device company headquartered in Tokyo, Japan, acquired MicroVention into their family of Companies. Terumo’s acquisition of MicroVention allowed both Companies to leverage their unique, proprietary technologies toward an increased focus on treating cerebrovascular diseases. Headquartered in California, MicroVention products are today sold in more than seventy countries through a direct sales organization alongside strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California and San José, Costa Rica. For more information on MicroVention, please visit www.microvention.com.
About Terumo Corporation
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large. For more information on Terumo, please visit www.terumo.com/about/profile.
** Editor’s Note: For a Clinical Glossary of Terms, please visit https://www.microvention.com/clinical-education/glossary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116517067/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tecnotree Reports Stable Revenue and Strong Profitability in Q1 2026 and Maintains Full-Year Guidance29.4.2026 14:06:00 CEST | Press release
Tecnotree, a global digital platform and services provider for AI-enabled 5G and cloud-native technologies, today announced its financial results for the first quarter of 2026, demonstrating stable revenue, strong profitability, and a robust order backlog despite geopolitical uncertainties across global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429319948/en/ Tecnotree Reports Stable Revenue and Strong Profitability in Q1 2026 and Maintains Full-Year Guidance Key Financial Highlights – Q1 2026 Revenue of EUR 16.8 million (16.9), revenue in constant currency EUR 17.1 million, +1.0% YoY. EBIT of EUR 4.6 million (4.5), +1.8% YoY. EBIT margin of 27.4% (26.9%), +50 basis points YoY. Foreign exchange (FX) gains EUR 1.0 million (-1.4). Net income EUR 2.1 million (1.5), +36.5% YoY. Free cash flow (FCF) EUR 0.2 million (1.0). Earnings per share (EPS) EUR 0.1 (0.1). Order book at the end of the period EUR 105.4 million
SS&C Unveils WorkHQ to Power Enterprise Agentic Automation29.4.2026 14:00:00 CEST | Press release
Agentic automation platform enables companies to control, govern and accelerate enterprise-wide adoption of AI SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the launch of SS&C Blue Prism WorkHQ, its agentic automation platform designed to help enterprises operationalize agentic AI safely, transparently and with full control of end-to-end workflows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429512507/en/ Unveiled at a live event at Nasdaq in New York City, WorkHQ introduces a unified control plane orchestrating people, AI agents, APIs and digital workers into a single governed environment. SS&C developed WorkHQ based on its own experience operating at scale across regulated industries. Today, SS&C supports more than 23,000 customers globally with the help of 4,000+ digital workers and more than 50 AI agents. These efforts have enabled SS&C to significantly improve operational efficiency in key proces
Ecolab Life Sciences Expands Global Bioprocessing Capabilities With New Advanced Development and Applications Center in Korea29.4.2026 14:00:00 CEST | Press release
New facility brings deep expertise closer to Asian customers, strengthening Ecolab’s global network Building on the continued growth and strong performance of its Life Sciences business, Ecolab is further expanding its global bioprocessing capabilities to support biopharmaceutical manufacturers worldwide. Today, Ecolab Life Sciences announced the opening of a new Bioprocessing Applications Lab (BPAL) in Dongtan, Korea, its first bioprocessing facility in Asia. The new center further strengthens the company’s global Life Sciences footprint and supports customers operating in one of the world’s most advanced biopharmaceutical manufacturing markets. The Korea BPAL supports a full range of process development activities from early-stage testing through studies that replicate manufacturing at scale, building on Ecolab’s established bioprocessing applications network in the United States and the United Kingdom. The facility enables hands-on collaboration with Ecolab’s bioprocessing experts t
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 13:42:00 CEST | Press release
Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bnAcquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditionsTransaction expected to close in Q3 2026 Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202604
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom